If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.765    0.00 (0.00%)
Bid:
2.60
Ask:
2.92
Spread: 0.32 (12.308%)
Market Cap: £5.04m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Receipt of Final Litigation Proceeds

24 Jan 2024 07:00

RNS Number : 6851A
Nanoco Group PLC
24 January 2024
 

FOR IMMEDIATE RELEASE 24 January 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS THE SAME HAS BEEN RETAINED IN UK LAW AS AMENDED BY THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR").

Nanoco Group plc

("Nanoco", the "Group", or the "Company")

 

Receipt of Final Litigation Proceeds

Proposals for Return of Capital to follow

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials emanating from its technology platform, today announces that it has received the second tranche of litigation proceeds from Samsung after settling last year on a no fault basis for the alleged infringement of the Group's IP.

The Group has received a net sum of $71.75m, being $75.0m less the expected Korean withholding tax, which amounted to $3.25m. The Korean withholding tax is available to offset Nanoco's future profits in the UK.

The Group previously announced the hedging of this tranche of proceeds at a rate of $1.22 / £1.00. The funds will be converted at this rate and generate a sterling receipt of £58.8m. This represents a gain of £2.1m compared to the current exchange rate for USD.

The Group is finalising its proposals for the amount and structure of the return of capital which can now go ahead following this receipt of the second tranche of litigation proceeds. The Group expects to update shareholders shortly on the final proposals which will be in line with the previously announced commitment to return between £33.0m and £40.0m to shareholders.

As previously communicated, the remaining proceeds will be invested in R&D and commercial activities to expand our range of high-performing materials, developing new materials with enhanced performance, as well as expanding our reach, a proactive IP licensing programme, payment of debt obligations, and to provide working capital through to the self-financing position that is expected during 2025.

Brian Tenner, Nanoco's CEO, commented:

"With receipt of these proceeds we can now finalise our plans for the significant return of capital to shareholders. The proceeds will also ensure that our commercial business is properly funded to take advantage of the growing commercial traction and development opportunities for our innovative platform technology."

- Ends -

 

The person responsible for arranging for the release of this announcement on behalf of Nanoco is Liam Gray, Company Secretary.

MAR

The information contained within this announcement is considered by the Company to contain inside information for the purposes of UK MAR. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

 

For further information, please contact:

Nanoco Group plc:

Brian Tenner, CEO ? +44 (0)1928 761 404

Liam Gray, CFO & Company Secretary

 

Cavendish Capital Markets Limited (Financial Adviser & Joint Corporate Broker):

Ed Frisby / George Lawson (Corporate Finance) +44 (0) 20 7220 0500

Tim Redfern / Charlie Combe (Corporate Broking)

Jasper Berry (Sales)

 

Turner Pope Investments (Joint Corporate Broker):

Andrew Thacker ? +44 (0) 20 3657 0050

James Pope

 

Powerscourt ? +44 (0)7970 246 725

Elly Williamson

Ollie Simmonds

Nanoco@powerscourt-group.com

 

FORWARD LOOKING STATEMENTS

This announcement (including information incorporated by reference in this announcement) and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

 

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

 

About Nanoco Group plc

 

Nanoco (LSE: NANO) is a nano-material production and licensing company, specialising in the production of its patented cadmium free quantum dots (CFQD®) and other patented nano-materials for use in the electronics industries.

Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build out a world-class, patent-protected IP portfolio alongside the scaling of the production for commercial orders.

Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Sensor, Electronics and Display markets. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of display applications. Nanoco's HEATWAVE? quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including cameras and image sensors.

Nanoco is listed on the Main Market of the London Stock Exchange, holds the LSE's Green Economy Mark, and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRQKNBKDBKBADB
Date   Source Headline
15th Mar 20227:00 amRNSNotice of Interim Results
4th Feb 20223:14 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
9th Dec 20217:00 amRNSBlock listing Six-Monthly Return
2nd Dec 20217:18 amRNSBlock Listing Application
1st Dec 202112:30 pmRNSDirector/PDMR Shareholding
1st Dec 202112:28 pmRNSAnnual General Meeting – Voting Results
30th Nov 20217:00 amRNSAGM Statement
18th Nov 20211:13 pmRNSDirector/PDMR Shareholding
9th Nov 20217:11 amRNSDirector/PDMR Shareholding
8th Nov 20217:00 amRNSDirector Appointment
5th Nov 202111:25 amRNSAdditional Work Package for European Customer
4th Nov 20216:20 pmRNSNotice of AGM
3rd Nov 20217:00 amRNSPreliminary Results
18th Oct 20216:10 pmRNSChange to final results announcement date
13th Oct 20219:30 amRNSPresentation via Investor Meet Company
8th Oct 20211:48 pmRNSNotice of Results
19th Aug 20217:00 amRNSNon-Executive Director Appointment
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.